ENTITY
Grifols

Grifols (GRFS US)

41
Analysis
Health Care • Spain
Grifols S.A. develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials.
more
bullish•Grifols SA
•20 Nov 2024 16:18

Lowball Non-Binding Indication from Brookfield

Rejected Offer: Grifols' independent committee rejected Brookfield's proposed valuation of €10.50 per Class A share, citing significant...

Share
bullish•Grifols SA
•18 Nov 2024 22:21

Liquid Universe of European Ordinary and Preferred Shares: November‘24 Report

Since mid-October, share-price spreads have generally tightened across European liquid universe of ordinary and preferred shares (10 have...

Share
bearish•Grifols SA
•29 Oct 2024 06:45

Brookfield Delays Its Takeover Bid for Grifols for a Second Time

Brookfield’s acquisition bid for Grifols has been delayed for a second time due to funding issues, raising investor concerns.

Share
•16 Oct 2024 20:13

Liquid Universe of European Ordinary and Preferred Shares: October‘24 Report

Since mid-September, share-price spreads have generally widened across our European liquid universe of ordinary and preferred shares (9 have...

Share
bullish•Grifols
•08 Oct 2024 10:41•Syndicated

Grifols A/B Spread (GRF.P) - Monday, Jul 8, 2024

A/B shares were issued in 2011 as part of an acquisition, allowing Grifols to expand its presence in the biopharmaceutical sector while maintaining...

Share
x